Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination.

Literature DB >> 15113932

Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination.

Lei Zhang¹, Ruy M Ribeiro, John R Mascola, Mark G Lewis, Gabriela Stiegler, Hermann Katinger, Alan S Perelson, Miles P Davenport.

Abstract

Passive antibody treatment of macaques prior to simian/human immunodeficiency virus infection produces "sterilizing immunity" in some animals and long-term reductions in viral loads in others. Analysis of viral kinetics suggests that antibody mediates sterilizing immunity by its effects on the initial viral inoculum. By contrast, reduction in peak viral load later in infection prevents CD4 depletion and contributes to long-term viral control.

Entities: Disease Gene

Mesh：

Substances：
Antibodies, Viral

Year: 2004 PMID： 15113932 PMCID： PMC400367 DOI： 10.1128/jvi.78.10.5520-5522.2004

Source DB: PubMed Journal: J Virol ISSN： 0022-538X Impact factor: 5.103

13 in total

1. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors: J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal: Nat Med Date: 2000-02 Impact factor: 53.440

2. Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles.

Authors: H Sato; J Orenstein; D Dimitrov; M Martin
Journal: Virology Date: 1992-02 Impact factor: 3.616

3. Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies.

Authors: F Notka; C Stahl-Hennig; U Dittmer; H Wolf; R Wagner
Journal: Vaccine Date: 1999-09 Impact factor: 3.641

4. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection.

Authors: J D Lifson; M A Nowak; S Goldstein; J L Rossio; A Kinter; G Vasquez; T A Wiltrout; C Brown; D Schneider; L Wahl; A L Lloyd; J Williams; W R Elkins; A S Fauci; V M Hirsch
Journal: J Virol Date: 1997-12 Impact factor: 5.103

5. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors: J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal: J Virol Date: 1999-05 Impact factor: 5.103

6. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors: P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal: J Virol Date: 2001-09 Impact factor: 5.103

7. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.

Authors: A Cafaro; A Caputo; C Fracasso; M T Maggiorella; D Goletti; S Baroncelli; M Pace; L Sernicola; M L Koanga-Mogtomo; M Betti; A Borsetti; R Belli; L Akerblom; F Corrias; S Buttò; J Heeney; P Verani; F Titti; B Ensoli
Journal: Nat Med Date: 1999-06 Impact factor: 53.440

8. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.

Authors: N L Letvin; S Robinson; D Rohne; M K Axthelm; J W Fanton; M Bilska; T J Palker; H X Liao; B F Haynes; D C Montefiori
Journal: J Virol Date: 2001-05 Impact factor: 5.103

9. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques.

Authors: L Foresman; F Jia; Z Li; C Wang; E B Stephens; M Sahni; O Narayan; S V Joag
Journal: AIDS Res Hum Retroviruses Date: 1998-08-10 Impact factor: 2.205

10. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.

Authors: S S Frankel; R M Steinman; N L Michael; S R Kim; N Bhardwaj; M Pope; M K Louder; P K Ehrenberg; P W Parren; D R Burton; H Katinger; T C VanCott; M L Robb; D L Birx; J R Mascola
Journal: J Virol Date: 1998-12 Impact factor: 5.103

5 in total

1. High-potency human immunodeficiency virus vaccination leads to delayed and reduced CD8+ T-cell expansion but improved virus control.

Authors: Miles P Davenport; Lei Zhang; Ansuman Bagchi; Arthur Fridman; Tong-Ming Fu; William Schleif; John W Shiver; Ruy M Ribeiro; Alan S Perelson
Journal: J Virol Date: 2005-08 Impact factor: 5.103

Review 5. Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors.

Authors: Ponraj Prabakaran; Antony S Dimitrov; Timothy R Fouts; Dimiter S Dimitrov
Journal: Adv Pharmacol Date: 2007